Hyperuricemia – 2019 Pipeline Insight Study – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Hyperuricemia
– Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s
offering.

The report offers comprehensive insights of the pipeline (under
development) therapeutics scenario and growth prospects across
Hyperuricemia development.

The report provides detailed coverage of the pipeline landscape for this
mechanism of action, equipped with data from multiple sources with
complete pipeline analysis by developmental stage, associated
indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental
Stages:

• Clinical
• Non-clinical
• Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for
Hyperuricemia

Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.

Scope of the Report

• The report provides a snapshot of the pipeline development for
  Hyperuricemia
• The report covers pipeline activity across the complete product
  development cycle i.e. clinical, pre-clinical and discovery stages for
  Hyperuricemia
• The report provides pipeline product profiles which includes product
  description, developmental activities, licensors & collaborators and
  chemical information
• Provides pipeline assessment by monotherapy and combination therapy
  products, stage of development, route of administration, and molecule
  type for Hyperuricemia
• The report also covers the dormant and discontinued pipeline projects
  related to Hyperuricemia

Reasons to Buy

• Establish comprehensive understanding of the pipeline activity across
  Hyperuricemia to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially
  lucrative portfolio in this space and create effective counter
  strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target
  finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the
  pipeline depth and focus of Hyperuricemia therapeutics
• Devise in licensing and out licensing strategies by identifying
  prospective partners with the most attractive projects to enhance and
  expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and
  understanding the factors that might have halted their progress

Key Topics Covered

1. Report Introduction

2. Hyperuricemia Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Hyperuricemia

4. Comparative Analysis

5. Products in Clinical Stage

• Product Description
• Research and Development
• Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment

• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

8. Inactive Products

• Product Description
• Research and Development
• Product Development Activities

Companies Mentioned

• AstraZeneca PLC
• CymaBay Therapeutics
• Kissei Pharmaceutical Co.
• LG Life Sciences
• Nippon Chemiphar Co.
• Polaris Pharmaceuticals
• Takeda Pharmaceutical Company Limited
• and more…

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gfzq79/hyperuricemia?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematological
Drugs